Shank‑associated RH domain‑interacting protein expression is upregulated in entodermal and mesodermal cancer or downregulated in ectodermal malignancy

Liang,Yanhua; Chen,Biao; Liu,Fen; Wang,Jiaman; Yang,Yao; Zheng,Yan; Tan,Shicui

doi:10.3892/ol.2018.9514

Shank‑associated RH domain‑interacting protein expression is upregulated in entodermal and mesodermal cancer or downregulated in ectodermal malignancy

Authors:
- Yanhua Liang
- Biao Chen
- Fen Liu
- Jiaman Wang
- Yao Yang
- Yan Zheng
- Shicui Tan
View Affiliations

Affiliations: Department of Dermatology, Cosmetology and Venereology, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong 518101, P.R. China, Department of Histology and Embryology, Institute of Neuroscience, Wenzhou Medical University, Wenzhou, Zhejiang 325035, P.R. China
Published online on: September 27, 2018 https://doi.org/10.3892/ol.2018.9514
Pages: 7180-7188
Copyright: © Liang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Shank‑associated RH domain‑interacting protein (SHARPIN) is a type of linear ubiquitin chain‑associated protein, which serves an important role in cell proliferation, apoptosis, organ development, immune and inflammatory reaction, initiation and development of malignant tumors. To evaluate SHARPIN expression in multiple malignant tumors derived from different germ layers, 14 types of cancer and their corresponding normal tissues were examined. Immunohistochemistry was performed to semi‑quantify SHARPIN expression in multiple malignant tumors, and immunofluorescence was performed to evaluate the subcellular localization of SHARPIN in various malignant tumors. All the recruited cancer and paracancer samples originated from entoderm and mesoderm showed an upregulated expression of SHARPIN, whereas the cancer types that originated from ectoderm exhibited a downregulated or loss of SHARPIN expression. SHARPIN was primarily localized in the cytoplasm of cells and exhibited a faint signal in the nucleus, with the exception for lung cancer and esophagus cancer, in which malignant cells had aberrantly large nuclei and limited cytoplasm, which produced a signal in the nucleus but not in the cytoplasm. Conclusively, SHARPIN expression was upregulated in entodermal and mesodermal cancer types, but downregulated in ectodermal cancer types, indicating SHARPIN could act as either oncogene or anti‑oncogene in malignant tumors derived from different germ layers.

View Figures

View References

1	McGuire S: World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv Nutr. 7:418–419. 2016. View Article : Google Scholar : PubMed/NCBI
2	Kaatsch P: Epidemiology of childhood cancer. Cancer Treat Rev. 36:277–285. 2010. View Article : Google Scholar : PubMed/NCBI
3	Lim S, Sala C, Yoon J, Park S, Kuroda S, Sheng M and Kim E: Sharpin, a novel postsynaptic density protein that directly interacts with the shank family of proteins. Mol Cell Neurosci. 17:385–397. 2001. View Article : Google Scholar : PubMed/NCBI
4	Hogenesch H, Gijbels MJ, Offerman E, van Hooft J, van Bekkum DW and Zurcher C: A spontaneous mutation characterized by chronic proliferative dermatitis in C57BL mice. Am J Pathol. 143:972–982. 1993.PubMed/NCBI
5	Seymour RE, Hasham MG, Cox GA, Shultz LD, Hogenesch H, Roopenian DC and Sundberg JP: Spontaneous mutations in the mouse Sharpin gene result in multiorgan inflammation, immune system dysregulation and dermatitis. Genes Immun. 8:416–421. 2007. View Article : Google Scholar : PubMed/NCBI
6	Jung J, Kim JM, Park B, Cheon Y, Lee B, Choo SH, Koh SS and Lee S: Newly identified tumor-associated role of human Sharpin. Mol Cell Biochem. 340:161–167. 2010. View Article : Google Scholar : PubMed/NCBI
7	Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, et al: Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 467:596–599. 2010. View Article : Google Scholar : PubMed/NCBI
8	Bii VM, Rae DT and Trobridge GD: A novel gammaretroviral shuttle vector insertional mutagenesis screen identifies SHARPIN as a breast cancer metastasis gene and prognostic biomarker. Oncotarget. 6:39507–39520. 2015. View Article : Google Scholar : PubMed/NCBI
9	De Melo J and Tang D: Elevation of SIPL1 (SHARPIN) increases breast cancer risk. PLoS One. 10:e01275462015. View Article : Google Scholar : PubMed/NCBI
10	Sieber S, Lange N, Kollmorgen G, Erhardt A, Quaas A, Gontarewicz A, Sass G, Tiegs G and Kreienkamp HJ: Sharpin contributes to TNFα dependent NFκB activation and anti-apoptotic signalling in hepatocytes. PLoS One. 7:e299932012. View Article : Google Scholar : PubMed/NCBI
11	Gerlach B, Cordier SM, Schmukle AC, Emmerich CH, Rieser E, Haas TL, Webb AI, Rickard JA, Anderton H, Wong WW, et al: Linear ubiquitination prevents inflammation and regulates immune signalling. Nature. 471:591–596. 2011. View Article : Google Scholar : PubMed/NCBI
12	Tomonaga M, Hashimoto N, Tokunaga F, Onishi M, Myoui A, Yoshikawa H and Iwai K: Activation of nuclear factor-kappa B by linear ubiquitin chain assembly complex contributes to lung metastasis of osteosarcoma cells. Int J Oncol. 40:409–417. 2012.PubMed/NCBI
13	Liang Y and Sundberg JP: SHARPIN regulates mitochondria-dependent apoptosis in keratinocytes. J Dermatol Sci. 63:148–153. 2011. View Article : Google Scholar : PubMed/NCBI
14	He L, Ingram A, Rybak AP and Tang D: Shank-interacting protein-like 1 promotes tumorigenesis via PTEN inhibition in human tumor cells. J Clin Invest. 120:2094–2108. 2010. View Article : Google Scholar : PubMed/NCBI
15	Shi Y, Paluch BE, Wang X and Jiang X: PTEN at a glance. J Cell Sci. 125:4687–4692. 2012. View Article : Google Scholar : PubMed/NCBI
16	Kwon RJ, Han ME, Kim JY, Liu L, Kim YH, Jung JS and Oh SO: ZHX1 promotes the proliferation, migration and invasion of cholangiocarcinoma cells. PLoS One. 11:e01655162016. View Article : Google Scholar : PubMed/NCBI
17	Ma X, Huang M, Wang Z, Liu B, Zhu Z and Li C: ZHX1 inhibits gastric cancer cell growth through inducing cell-cycle arrest and apoptosis. J Cancer. 7:60–68. 2016. View Article : Google Scholar : PubMed/NCBI
18	Wang Z, Potter CS, Sundberg JP and Hogenesch H: SHARPIN is a key regulator of immune and inflammatory responses. J Cell Mol Med. 16:2271–2279. 2012. View Article : Google Scholar : PubMed/NCBI
19	Tokunaga F, Nakagawa T, Nakahara M, Saeki Y, Taniguchi M, Sakata S, Tanaka K, Nakano H and Iwai K: SHARPIN is a component of the NF-κB-activating linear ubiquitin chain assembly complex. Nature. 471:633–636. 2011. View Article : Google Scholar : PubMed/NCBI
20	Rantala JK, Pouwels J, Pellinen T, Veltel S, Laasola P, Mattila E, Potter CS, Duffy T, Sundberg JP, Kallioniemi O, et al: SHARPIN is an endogenous inhibitor of β1-integrin activation. Nat Cell Biol. 13:1315–1324. 2011. View Article : Google Scholar : PubMed/NCBI
21	Landgraf K, Bollig F, Trowe MO, Besenbeck B, Ebert C, Kruspe D, Kispert A, Hänel F and Englert C: Sipl1 and Rbck1 are novel Eya1-binding proteins with a role in craniofacial development. Mol Cell Biol. 30:5764–5775. 2010. View Article : Google Scholar : PubMed/NCBI